<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386685</url>
  </required_header>
  <id_info>
    <org_study_id>TCD6595</org_study_id>
    <secondary_id>XRP9881</secondary_id>
    <nct_id>NCT00386685</nct_id>
  </id_info>
  <brief_title>XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer</brief_title>
  <official_title>Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (HerceptinÂ®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the activity of XRP9881 in combination with
      trastuzumab.

      The secondary objectives are safety and pharmacokinetic interaction
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (best overall response under treatment)</measure>
    <time_frame>study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 toxicities, pharmacokinetic interaction</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>larotaxel (XRP9881)</intervention_name>
    <description>intravenous administration</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>intravenous administration</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic breast cancer (MBC)

          -  HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ
             Hybridization) positive or IHC (Immunohistochemistry) 3+

          -  Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)

          -  Adequate organs functions

        Exclusion Criteria:

          -  More than one previous chemotherapy regimen for metastatic disease

          -  Cardiac dysfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri Roche, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud - Toulouse - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Breast</keyword>
  <keyword>metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

